MR targeted imaging for the expression of tenascin‐C in myocardial infarction in vivo

Abstract

1 Technical Efficacy: Stage 4 J. MAGN. RESON. IMAGING 2017;45:1668-1674.

In vivo MRI detection of atherosclerosis in ApoE-deficient mice by using tenascin-C-targeted USPIO

“…Then 100 µL of anti-mouse tenascin-C antibodies was added and stirred for 2 h at 37℃. Finally, the conjugated USPIO was purified with phosphate buffered saline (PBS) and stored in PBS (0.1 M, pH 7.4) at 4℃ (13,14).…”

“…After completing the reaction, the solution was ultrafiltered with a centrifugal filter device (300 Kd, PALL, Port Washington, NY, USA) to remove excess EDC.HCL and Sulfo-NHS. Then 100 mL of anti-mouse tenascin-C antibodies was added and stirred for 2 h at 37 C. Finally, the conjugated USPIO was purified with phosphate buffered saline (PBS) and stored in PBS (0.1 M, pH 7.4) at 4 C (13,14).…”

MiR-495-3p depletion contributes to myocardial ischemia/reperfusion injury in cardiomyocytes by targeting TNC

“…In addition, TNC inhibits cardiac endothelial cell spreading and enhances migration in response to angiogenic growth factors [ 12 ]. It has been found that TNC was identified as a gene that is abnormally expressed in MI/RI [ 13 , 14 ]. In addition, Jin et al.…”